Since ablation of tumor-derived PGRN was accompanied by an increase of CD8+T cell number at the tumor site, we reasoned that next evaluated whether depletion of tumor-derived PGRN might modify efficacy of anti-PD-1 therapy. This evidence concerns the gene PDCD1 and neoplasm.